Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ajovy is a prescription medicine containing fremanezumab-vfrm, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP). It is approved for preventive treatment of migraine in adults and episodic migraine in patients age 6 to 17 who weigh at least 45 kg. Ajovy is given by subcutaneous injection in monthly or quarterly regimens, depending on age and prescribed dosing.
read more about ajovy ...Fremanezumab-vfrm binds to the CGRP ligand and blocks it from attaching to its receptor. CGRP participates in migraine biology and pain signaling. Reducing CGRP activity lowers signaling associated with migraine attacks. Ajovy targets the CGRP molecule rather than the receptor and is used for prevention rather than treatment of an individual migraine attack after symptoms begin.
Ajovy is approved for migraine prevention in adults. It is also approved for preventive treatment of episodic migraine in patients age 6 to 17 who weigh 45 kg or more. The current label does not approve Ajovy for pediatric patients below 45 kg since an appropriate strength presentation is not available.
Adults receive 225 mg under the skin once monthly or 675 mg every three months, given as three consecutive 225 mg injections. Patients age 6 to 17 who weigh at least 45 kg receive 225 mg once monthly. Ajovy is injected into the abdomen, thigh, or upper arm. Trained patients age 13 and older or caregivers can administer selected doses.
Ajovy is contraindicated in people with serious hypersensitivity to fremanezumab-vfrm or its ingredients. Current warnings cover hypersensitivity reactions, constipation with serious complications, new or worsening high blood pressure, and new or worsening Raynaud's phenomenon. Injection-site reactions are the most commonly reported adverse reactions. Severe constipation, breathing trouble, swelling, or painful color changes in fingers or toes need medical assessment.
Yes. Ajovy is approved for migraine prevention in adults and for episodic migraine prevention in certain patients age 6 to 17.
Adults use either a monthly or every-three-month regimen. Eligible pediatric patients use the 225 mg monthly regimen.
Yes. Trained patients age 13 and older and caregivers can administer Ajovy according to the current instructions for use.
Yes. Current warnings include hypersensitivity, serious constipation complications, high blood pressure, and Raynaud's phenomenon.
AJOVY Autoinjector Instructions. https://www.ajovy.com/autoinjector. Date Accessed September 11, 2026.
AJOVY Dosing Options. https://www.ajovy.com/dosing. Date Accessed September 11, 2026.
AJOVY Prefilled Syringe Instructions. https://www.ajovy.com/prefilled-syringe. Date Accessed September 11, 2026.
DailyMed - AJOVY (fremanezumab-vfrm) Injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e344ea-5916-4947-b6f2-4a76ccc04b6b. Date Accessed September 11, 2026.
Fremanezumab-vfrm Injection. https://medlineplus.gov/druginfo/meds/a618053.html. Date Accessed September 11, 2026.